查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1941484

去識別化醫療資料市場規模、佔有率和趨勢分析報告：按資料類型、應用、最終用途、地區和細分市場預測（2026-2033 年）

De-identified Health Data Market Size, Share & Trends Analysis Report By Type of Data (Genomic Data, Prescription Data, Claims Data, Pharmacogenomic Data, Clinical Data), By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

匿名化醫療數據市場概覽

全球去識別化醫療數據市場預計在 2025 年達到 88 億美元，預計到 2033 年將達到 179.3 億美元。

預計從 2026 年到 2033 年，該市場將以 9.37% 的複合年成長率成長。推動該市場成長的因素是數據分析在醫療保健領域的日益普及，這使得大規模研究和預測建模能夠在不損害患者隱私的情況下進行。

GDPR 和 HIPAA 等法規結構進一步推動了去識別化資料的使用，以實現合規性。人工智慧和機器學習的進步推動了對符合隱私規定的大型資料集的需求，以改善診斷和治療方法。此外，穿戴式裝置、感測器和電子健康記錄 (EHR) 產生的數據激增，也擴大了去識別化資料二次利用的範圍。

去識別化的健康數據對於臨床研究至關重要，因為它使研究人員能夠在保護患者隱私的同時分析大規模資料集。這些數據可以識別趨勢、評估治療效果並支持人群健康研究，所有這些都不會洩露個人識別資訊。利用去識別化資料能夠幫助研究人員提高研究成果的質量，並推動醫學知識和實踐的進步。

例如，2023年4月，飛利浦與麻省理工學院醫學工程與科學研究所（IMES）合作開發了一套先進的重症監護資料集，旨在推進醫療保健領域的臨床研究與開發以及人工智慧應用。該資料集包含來自加護病房患者的匿名數據，並整合了全面的臨床資訊，以幫助研究人員和教育工作者深入了解重症監護，從而改善患者預後。這項措施將促進人工智慧驅動的醫療解決方案的創新，有助於實現更精準的診斷和個人化治療。

此外，去識別化技術能夠實現不同醫療系統間病患資料的安全共用，促進醫療領域的合作與創新，並推動診斷和治療技術的進步。它還能提供訓練人工智慧系統所需的關鍵數據，提高醫學影像在疾病檢測和分析中的準確性和效用。這種方法在保護病患隱私的同時，也有助於改善醫療效果。

例如，2023年12月，專注於將健康數據轉化為科研用途的軟體公司Inference, Inc.與喬治亞最大的學術醫療系統埃默里醫療保健中心（Emory Healthcare）合作，旨在改善對多樣化、匯總且去識別化數據的訪問。該計劃旨在加速研究進程，改善疾病診斷，並促進新治療方法的開發。此次合作體現了雙方致力於推動醫學知識、促進創新以及改善世界各地個人和社區健康福祉的共同承諾。

「與nference的合作使我們加入了一個由頂尖機構組成的聯合資料網路，為突破性研究奠定了基礎。我們將攜手提供全面、數據驅動的見解，以應對當今一些最重要的健康挑戰，改善人們的生活，並帶來希望。”

喬·德帕，埃默里醫療保健和埃默里大學首席數據和分析官

目錄

第1章調查方法和範圍

第2章執行摘要

3. 去識別化醫療資料市場變數、趨勢和範圍

  • 市場譜系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
  • 匿名化醫療數據市場分析工具
    • 產業分析：波特五力模型
    • PESTEL 分析

第4章：匿名化醫療數據市場：按數據類型分類的估算與趨勢分析

  • 按資料類型分類的市場佔有率（2025 年和 2033 年）
  • 全球去識別化醫療數據市場：按數據類型分類的展望
  • 臨床數據
  • 基因組數據
  • 患者人口統計學數據
  • 配方數據
  • 計費數據
  • 行為數據
  • 穿戴式裝置和感測器數據
  • 調查和患者報告數據
  • 影像資料
  • 檢查數據
  • 醫院和醫療服務提供者數據
  • 健康社會決定因素 (SDoH) 數據
  • 藥物基因組學數據
  • 生物識別數據
  • 營運和財務數據
  • 流行病學數據
  • 醫療利用數據
  • 其他

第5章：去識別化醫療資料市場：依最終用途分類的估算與趨勢分析

  • 按最終用途分類的市場佔有率（2025 年和 2033 年）
  • 全球去識別化醫療保健數據市場：按最終用途分類的展望
  • 製藥公司
  • 生技公司
  • 醫療設備製造商
  • 醫療保健提供者
  • 保險公司/醫療保險公司
  • 研究所
  • 政府機構
  • 其他

第6章：匿名化醫療數據市場：按應用分類的估算與趨勢分析

  • 按應用領域分類的市場佔有率（2025 年和 2033 年）
  • 全球去識別化醫療數據市場：按應用領域分類的展望
  • 臨床研究與測試
  • 公共衛生
  • 精準醫療
  • 衛生經濟學與結果研究（HEOR）
  • 人口健康管理
  • 藥物發現與開發
  • 提高醫療品質
  • 核保和風險評估
  • 市場進入和商業策略
  • 商業智慧和營運效率
  • 遠端醫療和遠距監測
  • 病人參與和支持計劃
  • 其他

7. 按地區、估算和趨勢分析、資料類型、最終用途和應用分類的去識別化醫療資料市場

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 全球市場概覽（按地區分類）
  • 市場規模及預測趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 創新者
  • 供應商概況
    • 主要經銷商和通路合作夥伴名單
    • 主要企業市佔率分析，2025 年
    • IQVIA
    • Oracle（Cerner Corporation）
    • Optum, Inc.（UnitedHealth Group）
    • ICON plc
    • Veradigm LLC（前身為 Allscripts）
    • IBM
    • Flatiron Health（F. Hoffmann-La Roche Ltd）
    • Premier, Inc.
    • Shaip
    • Komodo Health, Inc.
    • Evidation Health, Inc.
    • Medidata
    • Clarify Health Solutions
    • Satori Cyber Ltd.
Product Code: GVR-4-68040-481-1

De-identified Health Data Market Summary

The global de-identified health data market size was estimated at USD 8.80 billion in 2025 and is projected to reach USD 17.93 billion by 2033, growing at a CAGR of 9.37% from 2026 to 2033. The market is driven by the increasing integration of data analytics in healthcare, which supports large-scale studies and predictive modeling without breaching patient confidentiality.

Regulatory frameworks such as GDPR and HIPAA further incentivize using de-identified data for compliance. Advancements in AI and machine learning amplify the need for extensive, privacy-compliant datasets to improve diagnostic and therapeutic methods. In addition, the surge in data from wearable devices, sensors, and electronic health records (EHRs) has expanded the scope for de-identified data in secondary applications.

De-identified health data is essential for clinical research as it allows researchers to analyze large datasets while protecting patient privacy. This data identifies trends, evaluates treatment effectiveness, and supports population health studies without compromising individual identities. By leveraging de-identified data, researchers can enhance the quality of their findings and facilitate advancements in medical knowledge and practice.

For instance, in April 2023, Philips and the MIT Institute for Medical Engineering and Science (IMES) collaborated to develop an enhanced critical care dataset to advance clinical research and AI applications in healthcare. This dataset includes de-identified data from ICU patients and integrates comprehensive clinical information to support researchers and educators in gaining insights into critical care and improving patient outcomes. The initiative fosters innovation in AI-driven healthcare solutions, contributing to more accurate diagnostics and personalized treatments.

Furthermore, de-identification facilitates collaboration and innovation within the healthcare sector by enabling secure patient data sharing across various healthcare systems, thereby advancing diagnostic and treatment technologies. Moreover, it provides critical data necessary for training AI systems, enhancing the accuracy and relevance of medical imaging for disease detection and analysis. This approach protects patient privacy and drives improvements in healthcare outcomes.

For instance, in December 2023, nference, Inc., a software company focused on transforming healthcare data for research, partnered with Emory Healthcare, Georgia's largest academic health system, to enhance access to diverse, aggregated, de-identified data. This initiative aims to accelerate research efforts, improve disease diagnosis, and facilitate the development of new treatments. The collaboration reflects a mutual commitment to advancing medical knowledge, promoting innovation, and enhancing the health and well-being of individuals and communities globally.

"This collaboration with nference allows us to join a federated data network of leading institutions that will enable ground-breaking research. Together, we can work to improve lives and provide hope, tackling some of the most critical health care challenges of our time while delivering comprehensive, data-driven insights."

Joe Depa, chief data and analytics officer at Emory Healthcare and Emory University

Global De-identified Health Data Market Report Segmentation

This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 - 2033. For this report, Grand View Research has segmented the global de-identified health data market report based on type of data, application, end use, and region:

  • Type of Data Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical Data
  • Genomic Data
  • Patient Demographics
  • Prescription Data
  • Claims Data
  • Behavioral Data
  • Wearable and Sensor Data
  • Survey and Patient-Reported Data
  • Imaging Data
  • Laboratory Data
  • Hospital and Provider Data
  • Social Determinants of Health (SDoH) Data
  • Pharmacogenomic Data
  • Biometric Data
  • Operational and Financial Data
  • Epidemiological Data
  • Healthcare Utilization Data
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical Research and Trials
  • Public Health
  • Precision Medicine
  • Health Economics and Outcomes Research (HEOR)
  • Population Health Management
  • Drug Discovery and Development
  • Healthcare Quality Improvement
  • Insurance Underwriting and Risk Assessment
  • Market Access and Commercial Strategy
  • Business Intelligence and Operational Efficiency
  • Telemedicine and Remote Monitoring
  • Patient Engagement and Support Programs
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical Companies
  • Biotechnology Firms
  • Medical Device Manufacturers
  • Healthcare Providers
  • Insurance Companies/ Healthcare Payers
  • Research Institutions
  • Government Agencies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type of data
    • 1.1.2. End use
    • 1.1.3. Application
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
    • 1.6.3. Volume price analysis (Model 2)
    • 1.6.4. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type of data outlook
    • 2.2.2. End use outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. De-identified Health Data Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
    • 3.2.3. Market Opportunity analysis
  • 3.3. De-identified Health Data Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. De-identified Health Data Market: Type of Data Estimates & Trend Analysis

  • 4.1. Type of Data Market Share, 2025 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global De-identified Health Data Market by Type of Data Outlook
  • 4.4. Clinical Data
    • 4.4.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.5. Genomic Data
    • 4.5.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.6. Patient Demographics
    • 4.6.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.7. Prescription Data
    • 4.7.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.8. Claims Data
    • 4.8.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.9. Behavioral Data
    • 4.9.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.10. Wearable and Sensor Data
    • 4.10.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.11. Survey and Patient-Reported Data
    • 4.11.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.12. Imaging Data
    • 4.12.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.13. Laboratory Data
    • 4.13.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.14. Hospital and Provider Data
    • 4.14.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.15. Social Determinants of Health (SDoH) Data
    • 4.15.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.16. Pharmacogenomic Data
    • 4.16.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.17. Biometric Data
    • 4.17.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.18. Operational and Financial Data
    • 4.18.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.19. Epidemiological Data
    • 4.19.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.20. Healthcare Utilization Data
    • 4.20.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 4.21. Others
    • 4.21.1. Market estimates and forecast 2021 - 2033 (USD Million)

Chapter 5. De-identified Health Data Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2025 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global De-identified Health Data Market by End Use Outlook
  • 5.4. Pharmaceutical Companies
    • 5.4.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 5.5. Biotechnology Firms
    • 5.5.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 5.6. Medical Device Manufacturers
    • 5.6.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 5.7. Healthcare Providers
    • 5.7.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 5.8. Insurance Companies/ Healthcare Payers
    • 5.8.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 5.9. Research Institutions
    • 5.9.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 5.10. Government Agencies
    • 5.10.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 5.11. Others
    • 5.11.1. Market estimates and forecast 2021 - 2033 (USD Million)

Chapter 6. De-identified Health Data Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2025 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global De-identified Health Data Market by Application Outlook
  • 6.4. Clinical Research and Trials
    • 6.4.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.5. Public Health
    • 6.5.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.6. Precision Medicine
    • 6.6.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.7. Health Economics and Outcomes Research (HEOR)
    • 6.7.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.8. Population Health Management
    • 6.8.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.9. Drug Discovery and Development
    • 6.9.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.10. Healthcare Quality Improvement
    • 6.10.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.11. Insurance Underwriting and Risk Assessment
    • 6.11.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.12. Market Access and Commercial Strategy
    • 6.12.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.13. Business Intelligence and Operational Efficiency
    • 6.13.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.14. Telemedicine and Remote Monitoring
    • 6.14.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.15. Patient Engagement and Support Programs
    • 6.15.1. Market estimates and forecast 2021 - 2033 (USD Million)
  • 6.16. Others
    • 6.16.1. Market estimates and forecast 2021 - 2033 (USD Million)

Chapter 7. De-identified Health Data Market: Regional Estimates & Trend Analysis, By Type of Data, By End use, By Application

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size & Forecasts Trend Analysis, 2021 - 2033:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Mexico market estimates and forecasts 2021 - 2033 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2021 - 2033 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Singapore market estimates and forecasts 2021 - 2033 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Argentina market estimates and forecasts 2021 - 2033 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2021 - 2033 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Innovators
  • 8.4. Vendor Landscape
    • 8.4.1. List of key distributors and channel partners
    • 8.4.2. Key customers
    • 8.4.3. Key company market share analysis, 2025
    • 8.4.4. IQVIA
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Technology Type benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Oracle (Cerner Corporation)
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Technology Type benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Optum, Inc. (UnitedHealth Group)
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Technology Type benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. ICON plc
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Technology Type benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Veradigm LLC (Formerly known as Allscripts)
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Technology Type benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. IBM
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Technology Type benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Flatiron Health (F. Hoffmann-La Roche Ltd)
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Technology Type benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Premier, Inc.
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Technology Type benchmarking
      • 8.4.11.4. Strategic initiatives
    • 8.4.12. Shaip
      • 8.4.12.1. Company overview
      • 8.4.12.2. Financial performance
      • 8.4.12.3. Technology Type benchmarking
      • 8.4.12.4. Strategic initiatives
    • 8.4.13. Komodo Health, Inc.
      • 8.4.13.1. Company overview
      • 8.4.13.2. Financial performance
      • 8.4.13.3. Technology Type benchmarking
      • 8.4.13.4. Strategic initiatives
    • 8.4.14. Evidation Health, Inc.
      • 8.4.14.1. Company overview
      • 8.4.14.2. Financial performance
      • 8.4.14.3. Technology Type benchmarking
      • 8.4.14.4. Strategic initiatives
    • 8.4.15. Medidata
      • 8.4.15.1. Company overview
      • 8.4.15.2. Financial performance
      • 8.4.15.3. Technology Type benchmarking
      • 8.4.15.4. Strategic initiatives
    • 8.4.16. Clarify Health Solutions
      • 8.4.16.1. Company overview
      • 8.4.16.2. Financial performance
      • 8.4.16.3. Technology Type benchmarking
      • 8.4.16.4. Strategic initiatives
    • 8.4.17. Satori Cyber Ltd.
      • 8.4.17.1. Company overview
      • 8.4.17.2. Financial performance
      • 8.4.17.3. Technology Type benchmarking
      • 8.4.17.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America de-identified health data market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 4 North America de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 5 North America de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 6 U.S. de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 7 U.S. de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 8 U.S. de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 9 Canada de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 10 Canada de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 11 Canada de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 12 Mexico de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 13 Mexico de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 14 Mexico de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 15 Europe de-identified health data market, by region, 2021 - 2033 (USD Million)
  • Table 16 Europe de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 17 Europe de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 18 Europe de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 19 Germany de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 20 Germany de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 21 Germany de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 22 UK de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 23 UK de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 24 UK de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 25 France de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 26 France de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 27 France de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 28 Italy de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 29 Italy de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 30 Italy de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 31 Spain de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 32 Spain de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 33 Spain de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 34 Denmark de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 35 Denmark de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 36 Denmark de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 37 Sweden de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 38 Sweden de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 39 Sweden de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 40 Norway de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 41 Norway de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 42 Norway de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific de-identified health data market, by region, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 47 China de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 48 China de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 49 China de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 50 Japan de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 51 Japan de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 52 Japan de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 53 India de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 54 India de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 55 India de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 56 South Korea de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 57 South Korea de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 58 South Korea de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 59 Australia de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 60 Australia de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 61 Australia de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 62 Thailand de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 63 Thailand de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 64 Thailand de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 65 Latin America de-identified health data market, by region, 2021 - 2033 (USD Million)
  • Table 66 Latin America de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 67 Latin America de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 68 Latin America de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 69 Brazil de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 70 Brazil de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 71 Brazil de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 72 Argentina de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 73 Argentina de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 74 Argentina de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 75 MEA de-identified health data market, by region, 2021 - 2033 (USD Million)
  • Table 76 MEA de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 77 MEA de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 78 MEA de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 79 South Africa de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 80 South Africa de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 81 South Africa de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 85 UAE de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 86 UAE de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 87 UAE de-identified health data market, by application, 2021 - 2033 (USD Million)
  • Table 88 Kuwait de-identified health data market, by type of data, 2021 - 2033 (USD Million)
  • Table 89 Kuwait de-identified health data market, by end use, 2021 - 2033 (USD Million)
  • Table 90 Kuwait de-identified health data market, by application, 2021 - 2033 (USD Million)

List of Tables

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 De-identified Health Data market: market outlook
  • Fig. 9 De-identified Health Data competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 De-identified Health Data market driver impact
  • Fig. 15 De-identified Health Data market restraint impact
  • Fig. 16 De-identified Health Data market strategic initiatives analysis
  • Fig. 17 De-identified Health Data market: Type of Data movement analysis
  • Fig. 18 De-identified Health Data market: Type of Data outlook and key takeaways
  • Fig. 19 Clinical data market estimates and forecast, 2021 - 2033
  • Fig. 20 Genomic data market estimates and forecast, 2021 - 2033
  • Fig. 21 Patient demographics market estimates and forecast, 2021 - 2033
  • Fig. 22 Prescription data market estimates and forecast, 2021 - 2033
  • Fig. 23 Claims data market estimates and forecast, 2021 - 2033
  • Fig. 24 Behavioral data market estimates and forecast, 2021 - 2033
  • Fig. 25 Wearable and sensor data market estimates and forecast, 2021 - 2033
  • Fig. 26 Survey and patient-reported data market estimates and forecast, 2021 - 2033
  • Fig. 27 Imaging data market estimates and forecast, 2021 - 2033
  • Fig. 28 Laboratory data market estimates and forecast, 2021 - 2033
  • Fig. 29 Hospital and provider data market estimates and forecast, 2021 - 2033
  • Fig. 30 Social determinants of health (SDoH) data market estimates and forecast, 2021 - 2033
  • Fig. 31 Pharmacogenomic data market estimates and forecast, 2021 - 2033
  • Fig. 32 Biometric data market estimates and forecast, 2021 - 2033
  • Fig. 33 Operational and financial data market estimates and forecast, 2021 - 2033
  • Fig. 34 Epidemiological data market estimates and forecast, 2021 - 2033
  • Fig. 35 Healthcare utilization data market estimates and forecast, 2021 - 2033
  • Fig. 36 Others market estimates and forecast, 2021 - 2033
  • Fig. 37 De-identified Health Data market: End use analysis
  • Fig. 38 De-identified Health Data market: End use outlook and key takeaways
  • Fig. 39 Pharmaceutical companies market estimates and forecast, 2021 - 2033
  • Fig. 40 Biotechnology firms market estimates and forecast, 2021 - 2033
  • Fig. 41 Medical device manufacturers market estimates and forecast, 2021 - 2033
  • Fig. 42 Healthcare providers market estimates and forecast, 2021 - 2033
  • Fig. 43 Insurance companies/ Healthcare payers market estimates and forecast, 2021 - 2033
  • Fig. 44 Research institutions market estimates and forecast, 2021 - 2033
  • Fig. 45 Government agencies market estimates and forecast, 2021 - 2033
  • Fig. 46 Others market estimates and forecast, 2021 - 2033
  • Fig. 47 De-identified Health Data market: Application movement analysis
  • Fig. 48 De-identified Health Data market: Application outlook and key takeaways
  • Fig. 49 Clinical research and trials market estimates and forecast, 2021 - 2033
  • Fig. 50 Public health market estimates and forecast, 2021 - 2033
  • Fig. 51 Precision medicine market estimates and forecast, 2021 - 2033
  • Fig. 52 Health economics and outcomes research (HEOR) market estimates and forecast, 2021 - 2033
  • Fig. 53 Population health management market estimates and forecast, 2021 - 2033
  • Fig. 54 Drug discovery and development market estimates and forecast, 2021 - 2033
  • Fig. 55 Healthcare quality improvement market estimates and forecast, 2021 - 2033
  • Fig. 56 Insurance underwriting and risk assessment market estimates and forecast, 2021 - 2033
  • Fig. 57 Market access and commercial strategy market estimates and forecast, 2021 - 2033
  • Fig. 58 Business intelligence and operational efficiency market estimates and forecast, 2021 - 2033
  • Fig. 59 Telemedicine and remote monitoring market estimates and forecast, 2021 - 2033
  • Fig. 60 Patient engagement and support programs market estimates and forecast, 2021 - 2033
  • Fig. 61 Others market estimates and forecast, 2021 - 2033
  • Fig. 62 Global de-identified health data market: Regional movement analysis
  • Fig. 63 Global de-identified health data market: Regional outlook and key takeaways
  • Fig. 64 North America market estimates and forecasts, 2021 - 2033
  • Fig. 65 U.S. key country dynamics
  • Fig. 66 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 67 Canada key country dynamics
  • Fig. 68 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 69 Mexico key country dynamics
  • Fig. 70 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 71 Europe
  • Fig. 72 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 73 UK key country dynamics
  • Fig. 74 UK market estimates and forecasts, 2021 - 2033
  • Fig. 75 Germany key country dynamics
  • Fig. 76 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 77 France key country dynamics
  • Fig. 78 France market estimates and forecasts, 2021 - 2033
  • Fig. 79 Italy key country dynamics
  • Fig. 80 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 81 Spain key country dynamics
  • Fig. 82 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 83 Denmark key country dynamics
  • Fig. 84 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 85 Sweden key country dynamics
  • Fig. 86 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 87 Norway key country dynamics
  • Fig. 88 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 89 Asia Pacific
  • Fig. 90 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 91 China key country dynamics
  • Fig. 92 China market estimates and forecasts, 2021 - 2033
  • Fig. 93 Japan key country dynamics
  • Fig. 94 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 95 India key country dynamics
  • Fig. 96 India market estimates and forecasts, 2021 - 2033
  • Fig. 97 Thailand key country dynamics
  • Fig. 98 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 99 South Korea key country dynamics
  • Fig. 100 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 101 Australia key country dynamics
  • Fig. 102 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 103 Latin America
  • Fig. 104 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 105 Brazil key country dynamics
  • Fig. 106 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 107 Argentina key country dynamics
  • Fig. 108 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 109 Middle East and Africa
  • Fig. 110 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 111 South Africa key country dynamics
  • Fig. 112 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 113 Saudi Arabia key country dynamics
  • Fig. 114 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 115 UAE key country dynamics
  • Fig. 116 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 117 Kuwait key country dynamics
  • Fig. 118 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 119 Market share of key market